Iridex Corp (IRIX)

Iridex Stock Analysis & Ratings

IRIX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.88 - $9.46
Previous Close$3.07
Average Volume (3M)39.50K
Market Cap$48.77M
P/E Ratio-8.6
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-0.36



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Iridex’s price range in the past 12 months?
Iridex lowest stock price was $2.88 and its highest was $9.46 in the past 12 months.
    What is Iridex’s market cap?
    Iridex’s market cap is $48.77M.
      What is Iridex’s price target?
      The average price target for Iridex is $9.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 193.16% Increase from the current price of $3.07.
        What do analysts say about Iridex?
        Iridex’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Iridex’s upcoming earnings report date?
          Iridex’s upcoming earnings report date is Aug 11, 2022 which is in 77 days.
            How were Iridex’s earnings last quarter?
            Iridex released its earnings results on May 12, 2022. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
              Is Iridex overvalued?
              According to Wall Street analysts Iridex’s price is currently Undervalued.
                Does Iridex pay dividends?
                Iridex does not currently pay dividends.
                What is Iridex’s EPS estimate?
                Iridex’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Iridex have?
                Iridex has 15,890,000 shares outstanding.
                  What happened to Iridex’s price movement after its last earnings report?
                  Iridex reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 2.484%.
                    Which hedge fund is a major shareholder of Iridex?
                    Currently, no hedge funds are holding shares in IRIX


                    Iridex Stock Analysis

                    The Iridex stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Iridex Corp

                    IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

                    Similar Stocks
                    Price & Change
                    Second Sight Medical Products
                    Staar Surgical
                    Escalon Medical

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis